drugset
drugset / Trial / NCT02164084

A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris

NCT02164084 ↗

Phase 1 Completed 18 enrolled Novan, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

This study will identify how much (if any) drug is absorbed from the skin of subjects with acne vulgaris after topical application of SB204.

Timeline

Start
2014-06
Primary completion
2014-06
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject BERDAZIMER SODIUM Small molecule 8 % Topical

Indications

acne